These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11127891)

  • 1. Binding properties of an orally active platinum anti-tumor drug JM216 with metallothionein in vivo.
    Xing B; Zhu H; Wang Y; Tang W
    Biometals; 2000 Sep; 13(3):203-8. PubMed ID: 11127891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of sodium chloroplatinate and iproplatin with metallothionein in vivo.
    Zhong W; Zhang Q; Yan Y; Yue S; Zhang B; Tang W
    J Inorg Biochem; 1997 May; 66(3):159-64. PubMed ID: 9130391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro binding of an orally active platinum antitumor drug, JM216 to metallothionein.
    Xing B; Zhu H; Shi Y; Tang W
    Biometals; 2001 Mar; 14(1):51-7. PubMed ID: 11368275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of cis- and trans-diamminedichloroplatinum with metallothionein in vivo.
    Zhang B; Huang H; Tang W
    J Inorg Biochem; 1995 Apr; 58(1):1-8. PubMed ID: 7738537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
    Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
    Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biotransformation of the platinum drug JM216 following oral administration to cancer patients.
    Raynaud FI; Mistry P; Donaghue A; Poon GK; Kelland LR; Barnard CF; Murrer BA; Harrap KR
    Cancer Chemother Pharmacol; 1996; 38(2):155-62. PubMed ID: 8616906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
    Raynaud FI; Odell DE; Kelland LR
    Br J Cancer; 1996 Aug; 74(3):380-6. PubMed ID: 8695352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo and in vitro binding of platinum to metallothionein.
    Zelazowski AJ; Garvey JS; Hoeschele JD
    Arch Biochem Biophys; 1984 Feb; 229(1):246-52. PubMed ID: 6538400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Mellish KJ; Kelland LR
    Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reaction of a platinum(IV) complex with native Cd,Zn-metallothionein in vitro.
    Zhong W; Zhang Q; Yan Y; Yue S; Zhang B; Tang W
    J Inorg Biochem; 1997 May; 66(3):179-85. PubMed ID: 9130392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ; Kelland LR; Harrap KR
    Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding properties and stoichiometries of a palladium(II) complex to metallothioneins in vivo and in vitro.
    Zhang Q; Zhong W; Xing B; Tang W; Chen Y
    J Inorg Biochem; 1998 Dec; 72(3-4):195-200. PubMed ID: 10065537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
    Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
    McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
    Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
    Kurata T; Tamura T; Sasaki Y; Fujii H; Negoro S; Fukuoka M; Saijo N
    Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platinum binding to metallothionein. Analysis of circular dichroism spectra of complexes formed between metallothionein and platinum from cis- and trans-diamminedichloroplatinum.
    Zhang B; Tang W; Gao S; Zhou Y
    J Inorg Biochem; 1995 Apr; 58(1):9-19. PubMed ID: 7738541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of platinum with metallothionein-like ligands in the rat kidney after administration of cis-dichlorodiammine platinum II.
    Mason R; Edwards IR; McLaren SJ
    Chem Biol Interact; 1984 Apr; 49(1-2):165-76. PubMed ID: 6539175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interactions of cis-diamminedichloroplatinum with metallothionein and glutathione in rat liver and kidney.
    Suzuki CA; Cherian MG
    Toxicology; 1990 Nov; 64(2):113-27. PubMed ID: 1977210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.